Document:

PATENT LICENSE AGREEMENT

This  Patent  License Agreement (the "AGREEMENT") is entered into by and between
Integral  Technologies,  Inc.,  a Nevada corporation located at 805 West Orchard
Street,  #7,  Bellingham, WA 98225 ("INTEGRAL") and  Knowles Electronics, LLC, a
Delaware  corporation  with  offices  at  1151 Maplewood Drive, Itasca, Illinois
60143  ("COMPANY")  and  is  effective  as  of  January  18,  2007  .

WHEREAS, Integral is the owner of certain technology, generally characterized as
ElectriPlast  technology;

WHEREAS, particular applications of the technology are covered by certain patent
rights  defined  below  and  those  patent  rights  are  owned  by Integral; and

WHEREAS,  Company wishes to obtain a non-exclusive license under such patents to
develop,  manufacture,  and  sell  certain  products.

NOW, THEREFORE, in consideration of the promises and of the mutual covenants and
agreements  herein  contained,  receipt  and  sufficiency  of  which  is  hereby
acknowledged,  the  Parties  hereby  agree  as  follows:

1.     DEFINITIONS.

     1.1.     "CONFIDENTIAL  INFORMATION"  means  all  non-public  information
regarding  the  Disclosing  Party  or its business activities, including without
limitation  (i) its sublicensees, manufacturers, contractors, or sales, (ii) any
non-public  information  disclosed  in any report provided under this Agreement,
(iii)  the  Documentation  and  any  other  information  disclosed  during  any
consulting  services;  (v)  the terms of this Agreement; and (v) any information
disclosed  by  Company  pursuant  to  Section  3.

     1.2.     "LICENSED  FIELD"  means the manufacture and sale of EMF PROTECTED
MOLDED  COMPONENTS  by  Company.
                               -

     1.3.      "LICENSED  PRODUCT"  means  any  Product  made,  used,  sold,  or
otherwise disposed of by or for Company that (i) uses the Raw Materials and (ii)
is  either  branded  with  a Company brand or is designed by Company and sold in
Company's  ordinary  course  of  business.

     1.4.      "LICENSED  PATENTS"  means  the  (i)  patents, provisional patent
applications, and  utility  patent applications set forth in Exhibit A; (ii) any
                                                             ---------
divisions, continuations, continuations-in-part, reissues, or re-examinations of
such  patents  and  patent  applications;  (iii) all foreign counterparts of the
foregoing  (i)  and (ii); and (iv) all applications for any of the foregoing (i)
through (iii).  Licensed Patents do not include any patent claim that has either
expired  or  been  held  invalid  or  unenforceable  by a decision of a court or
governmental agency of competent jurisdiction, which decision is unappealable or
unappealed  within the time allowed for an appeal, or any other patent or patent
application.

     1.5.     "PRODUCT"  means any product (i) the manufacture, use, sale, offer
for  sale,  or  import of which is covered by at least one claim of the Licensed
Patents;  or  (ii) produced by a process, the practice of which is covered by at
least  one  claim  of  the  Licensed  Patents.

     1.6.     "RAW  MATERIALS"  means the Technology, as Integral provides it to
Company,  on  a  per  weight  basis  for use in manufacturing Licensed Products.

     1.7.     "TECHNOLOGY"  means  Integral's  proprietary  ElectriPlast(TM)
technology,  portions  of  which  may  be  covered by the Licensed Patents.  The
Technology  is  a  compounded,  pelletized formulation of resin-based materials,
which  are  conductively loaded or doped with a proprietary controlled, balanced
concentration  of  micron conductive materials contained within the manufactured
pellet.  The conductive loading or doping within this pellet is then homogenized
using  conventional  molding  techniques and conventional molding equipment. The
resulting  polymer  is  electrically  conductive.

     1.8.     "THIRD  PARTY"  means corporate entities or individuals other than
Integral  or  Company.

                     Integral Proprietary and Confidential
                                 Page 1 of 6

<PAGE>
2.     CONSULTING  SERVICES.

Integral will provide Company with consulting services related to the Technology
at  Integral's standard hourly rates for such consulting services, on a date and
at  a  location mutually agreeable to the Parties.  If Company requests that all
or  part  of  the  consulting  services  take  place  at  facilities  other than
Integral's place of business, Company will reimburse Integral for its reasonable
and actual meals, travel, and lodging expenses incurred as a result of providing
such  consulting  services.  Integral  may,  but  is  not  obligated to, provide
Company  with certain pre-existing or developed written materials as part of the
consulting  services  ("DOCUMENTATION"),  provided  that  in  no event shall any
Documentation  be  deemed  a "work made for hire" or any ownership rights in the
Documentation  be  assigned  to  Company.  Documentation  shall  be  treated  as
Confidential  Information.

3.     LICENSE  GRANTS.

     3.1.     To Company.  Integral grants to Company a non-exclusive, worldwide
              ----------
license  under  the  Licensed  Patents  to (i) make (including the right to have
others  make),  use,  offer  to  sell,  sell  or import Licensed Products in the
Licensed  Field; (ii) the right to grant a sub-license to Company's customers to
use  Licensed  Products;  and  (iii)  internally  use  the  Documentation  and
information  provided  solely  for  purposes  of  developing  and  manufacturing
Licensed  Products  in  the  Licensed  Field.

     3.2.     Ownership.  Except  as  expressly  set  forth  in  this Agreement,
              ----------
nothing in this Agreement shall be construed as a grant of any license or rights
by implication or estoppel and Integral retains all right, title and interest in
and  to  the  Licensed  Patents.  All  rights  not expressly granted by Integral
hereunder  are  reserved  and retained by Integral, including but not limited to
Integral's  rights  in  the  Technology  not  covered  by  the Licensed Patents.

     3.3.     New  Joint  Developments.  All  technology,  information  and
              ------------------------
inventions ("New Developments"), whether or not patentable, developed jointly by
Integral  and  Company that concern the Technology (including the manufacture or
formulation  of  the Raw Materials) shall be the exclusive property of Integral.
All  New  Developments, whether or not patentable, developed jointly by Integral
and  Company  that concern the design or manufacture of fabricated products made
using  the  Raw  Materials  shall be the exclusive property of Company; provided
that  Company  shall have no rights in the Technology or Licensed Patents except
as  provided  pursuant  to the delivery of Raw Materials by Integral.  All other
New  Developments jointly developed by the Parties under this Agreement shall be
jointly  owned by the Parties; provided that Company shall have no rights in the
Technology  or  Licensed  Patents except as provided pursuant to the delivery of
Raw  Materials  by Integral.  The Parties agree to discuss in good faith whether
and  how  to jointly prosecute or enforce any patents based on jointly owned New
Developments  in a mutually agreed fashion.  Neither Party shall be obligated to
pay the other any royalties or other consideration, nor account to the other for
any  royalties  or  other  consideration  it  may  receive,  for  any  licenses,
assignment,  sale,  lease  or  other  distribution  of  the  jointly  owned  New
Developments  or  any  derivative  technology  thereof.  Any  such  derivative
technology  made  after the termination or expiration of this Agreement shall be
owned  exclusively  by the creator of such derivative technology.  Additionally,
regardless  of  subject  matter, all New Developments discovered or developed by
one  Party  without  the  participation of the other Party shall become the sole
property  of  the  discovering  or developing Party; provided that Company shall
have no rights in the Technology or Licensed Patents except as provided pursuant
to  the  delivery  of  Raw  Materials  by  Integral.

4.     CONSIDERATION.

Upon  execution  of  this Agreement, Company shall pay Integral a non-refundable
fee  of  One  U.S.  Dollar  ($1.00).

5.     RAW  MATERIALS  FEES.

                      INTEGRAL PROPRIETARY AND CONFIDENTIAL
                                  PAGE 2 OF 6

<PAGE>
The  Parties  agree to use good faith efforts to reach agreement on commercially
reasonable terms for the pricing and delivery of the Raw Materials to Company by
Integral, and that agreement regarding the pricing and delivery of Raw Materials
shall  be  memorialized  as  an  amendment  to  this  Agreement.

6.     ENFORCEMENT  OF  PATENT  RIGHTS.

     6.1.     Notice;  Enforcement.  In  the event that Company becomes aware of
              --------------------
actual  or  threatened  infringement  of  the  Patent  Rights  by  a Third Party
involving  Licensed Products, Company shall promptly notify Integral in writing.
Integral may, at its discretion, take corrective action against the Third Party,
and  may identify Company as having rights under the Licensed Patents.  Integral
shall  not  name  Company  as  a  co-party in any such action without an express
written  request  from  Company.

     6.2.     Infringement Action.  In the event Integral brings an infringement
              -------------------
action  against a Third Party, such action shall be at no cost to Company unless
Company  joins  the  suit  as  a  co-party,  and any recovery shall go solely to
Integral.  Company  is  under no obligation to join any such action and Integral
must  approve  the  addition  of  Company  as  a  co-party.

7.     TERM  AND  TERMINATION.

     7.1.     Term.  This  Agreement  shall be in full force and effect from the
              ----
Effective  Date  and  shall  remain  in  effect until the expiration of the last
patent  contemplated  to  be  licensed  by  this  Agreement,  or until otherwise
terminated  pursuant  to  the  terms  and  conditions  of  this  Agreement.

     7.2.     Termination.  Company  may  terminate  this  Agreement upon thirty
              -----------
(30) days' written notice at any time without cause.  Either Party may terminate
this Agreement immediately upon written notice at any time if the other Party is
in material breach of any material warranty, term or condition of this Agreement
and  has failed to cure that breach within thirty (30) days after written notice
thereof.  Integral may terminate this Agreement upon written notice in the event
(i)  Company  institutes  any  action  or proceeding in which it claims that any
Licensed  Patent  is  invalid  or  unenforceable; or (ii) Company institutes any
action  (including  by  counter or cross-claim) alleging that Integral infringes
any  Company patent and/or patent application.  The terminating Party will incur
no  liability  to  the other Party for damages of any kind resulting solely from
terminating  this  Agreement  in  accordance  with  its  terms.

     7.3.     Effect  of  Expiration  or  Termination.  Upon  expiration  or
              ---------------------------------------
termination  of this Agreement, (i) Company shall pay all sums accrued hereunder
prior to such termination, (ii) Integral shall have the right to retain any sums
already  paid by Company for this license and for any Raw Materials delivered or
created  for Company prior to expiration or termination, and (iii) Company shall
return  or certify in writing that it has destroyed all Documentation.  Upon the
termination  of  this Agreement, Company shall have the right to use or sell all
Licensed  Product on-hand at the time of such termination, provided that Company
shall  be obliged to pay Integral a royalty on use or such sales as set forth in
this  Agreement.

     7.4.     Survival.  In  the  event  of  expiration  or  termination of this
              --------
Agreement  for  any reason, the following sections will survive such termination
or  expiration:  1,  3.3,  7.4,  and  8  -  11.

8.     WARRANTIES,  REPRESENTATIONS,  AND  COVENANTS;  DISCLAIMER.

     8.1.     Mutual  Representations  and  Warranties.  Each  Party represents,
              ----------------------------------------
warrants,  and  covenants  that:  (i)  this  Agreement has been duly and validly
executed  and  delivered  by  such  Party  and  constitutes  a legal and binding
obligation  of  such Party, enforceable against it in accordance with its terms;
(ii)  such Party has all necessary power and authority to execute and perform in
accordance  with  this Agreement; and (iii) such Party's execution, delivery and
performance of this Agreement will not conflict with or violate any provision of
law,  rule  or  regulation  to  which  it  is subject, or any agreement or other
obligation  directly  or indirectly applicable to such Party or binding upon its
assets.

     8.2.     Representations  and  Warranties of Integral.  Integral represents
              --------------------------------------------
and  warrants  that  (i)  it has the lawful right to grant the license set forth
herein;  and  (ii)  as  of  the  Effective  Date,  the  Licensed  Patents

                      INTEGRAL PROPRIETARY AND CONFIDENTIAL
                                  PAGE 3 OF 6

<PAGE>
listed  in  Exhibit  A are issued, unexpired, valid according to the U.S. Patent
and  Trademark  Office  and  in  good  standing.

     8.3.     Representations,  Warranties,  and  Covenants of Company.  Company
              --------------------------------------------------------
warrants that it has and will have throughout the Term the lawful right to grant
the  licenses  contemplated  herein.

     8.4.     WARRANTY  DISCLAIMER.  EXCEPT AS PROVIDED IN SECTIONS 7.1, AND 7.2
              --------------------
ABOVE,  INTEGRAL  EXPRESSLY  DISCLAIMS  ALL  WARRANTIES,  EXPRESS,  IMPLIED  OR
STATUTORY,  INCLUDING  BUT  NOT  LIMITED  TO  ANY  IMPLIED  WARRANTIES  OF
MERCHANTABILITY,  FITNESS FOR A PARTICULAR PURPOSE, OR NONINFRINGEMENT, ALL WITH
RESPECT  TO  THE PATENTS, DOCUMENTATION, AND ANY OTHER MATERIALS OR INTELLECTUAL
PROVIDED  OR  LICENSED  UNDER  THIS  AGREEMENT.  IN  ADDITION,  NOTHING  IN THIS
AGREEMENT  SHALL BE CONSTRUED AS (I) A WARRANTY OR REPRESENTATION BY INTEGRAL OF
THE  VALIDITY  OR  SCOPE  OF  ANY  OF  THE  LICENSED PATENTS; (II) A WARRANTY OR
REPRESENTATION  THAT  ANYTHING  MADE,  USED, SOLD OFFERED FOR SALE, IMPORTED, OR
OTHERWISE DISPOSED OF UNDER ANY LICENSE GRANTED IN THIS AGREEMENT IS OR SHALL BE
FREE  FROM  INFRINGEMENT  OF  PATENTS OR PROPRIETARY RIGHTS OF THIRD PARTIES; OR
(III)  AN  AGREEMENT  BY INTEGRAL TO BRING OR PROSECUTE ACTIONS OR SUITS AGAINST
THIRD  PARTIES  FOR  INFRINGEMENT  OF  THE  PATENT  RIGHTS.

9.     INDEMNIFICATION.

Each  Party (the "INDEMNIFYING PARTY") will indemnify, hold harmless, and defend
the  other  Party  (the  "INDEMNIFIED  PARTY")  and  its  subsidiary  and parent
entities,  successors,  affiliates,  and  assigns,  and  all of their respective
officers,  directors,  members,  stockholders, agents, employees, and attorneys,
from any and all actions, causes of action, suits, proceedings, claims, demands,
judgments,  bona  fide  settlements,  penalties,  damages,  losses, liabilities,
costs, and expenses (including without limitation reasonable attorneys' fees and
costs and those necessary to interpret or enforce this Section 9) arising out of
or  relating  to  any  claim  or  allegation arising out of (i) the Indemnifying
Party's  breach  of  this Agreement, including without limitation the warranties
set  forth  in  Section  8  above;  or  (ii)  in  the  case where Company is the
Indemnifying  Party,  the  manufacture,  use,  or  sale of any Licensed Product,
including, but not limited to any damages, losses or liabilities whatsoever with
respect to death or injury to any person and damage to any property arising from
the  possession,  use  or  operation of the Licensed Product by Company or their
customers  in any manner whatsoever; except to the extent that the claim results
from  Integral's  infringement  of the intellectual property rights of any third
party.  The  Indemnified  Party  may, at its expense, employ separate counsel to
monitor  and participate in the defense of any claim that the Indemnifying Party
is  defending  under  this  Section.  The  Indemnified  Party  will  provide the
Indemnifying  Party  with  reasonably  prompt  notice in writing of any claim to
which  this  Section  relates.

10.     CONFIDENTIALITY.

A  Party receiving Confidential Information (the "RECEIVING PARTY") of the other
Party  (the "DISCLOSING PARTY") shall not disclose or make any use of any of the
Disclosing  Party's  Confidential  Information except expressly as authorized in
writing  by  the  Disclosing  Party.  Authorized uses include use related to the
implementation  of this Agreement.  The Receiving Party agrees to take all steps
reasonably  requested  by  the  Disclosing  Party  to  confirm  and  protect the
Disclosing  Party's  interests in the Confidential Information.  For purposes of
clarification,  Confidential  Information shall not include information that the
Receiving  Party can establish by written evidence:  (i) entered or subsequently
enters  the public domain without the Receiving Party's breach of any obligation
owed the Disclosing Party; (ii) became known to the Receiving Party prior to the
Disclosing  Party's disclosure of such information to the Receiving Party; (iii)
became  known  to  the  Receiving  Party from a source other than the Disclosing
Party  other  than by the breach of an obligation of confidentiality owed to the
Disclosing  Party;  or  (iv)  is  independently developed by the Receiving Party
without  reference  to  any  of the Disclosing Party's Confidential Information.

                      INTEGRAL PROPRIETARY AND CONFIDENTIAL
                                  PAGE 4 OF 6

<PAGE>
11.     GENERAL.

     11.1.     Notices.  All  notices,  requests,  consents,  approvals,  or
               -------
authorizations  in connection with this Agreement: (i) must be given in writing;
and (ii) will be deemed given as of (a) the day they are delivered on paper by a
nationally recognized express delivery service (such as Federal Express or DHL),
addressed  as set forth below; or (b) three (3) days after they are deposited in
the  sender's  national  mail  system, postage prepaid, certified or registered,
return  receipt  requested,  and  addressed  as  follows:

     To  Integral:  805  West  Orchard  Street,  #7, Bellingham, WA 98225, Attn:
     ------------
                    William  Robinson

     To  Company:  1151  Maplewood  Drive, Itasca, Illinois, 60143, Attn: Robert
     -----------
                   Walter

     Either  Party  may  change  the address above by giving notice to the other
     Party  pursuant  to  this  Section  11.1.

     11.2.     Assignment.  Integral may assign this Agreement or its rights and
               ----------
duties  under  this  Agreement,  but Company may not undertake any assignment of
this  Agreement  or  any  of  its rights and duties under this Agreement without
Integral's  prior  written  consent.  However, Company may assign this Agreement
without  Integral's  prior  written  consent  as  part of a merger, or a sale or
transfer of all or substantially all of its assets, provided such merger or sale
is not with or to a competitor of Integral.  Any attempted assignment by Company
of  this  Agreement  or  all or part of its rights and/or obligations under this
Agreement  without  Integral's  prior written consent (except as provided by the
prior sentence) will be voidable at Integral's option.  This Agreement will bind
each  Party's  heirs  and  personal representatives, and inure to the benefit of
each  Party  and  its  successors,  heirs  and/or  personal  assigns.

     11.3.     Dispute  Resolution.  This  Agreement  will  be  governed  by and
               -------------------
construed  in  accordance  with the laws of the State of Washington as such laws
apply  to  contracts performed within Washington by its residents.  Any cause of
action  concerning  this contract shall be brought in the state court located in
Whatcom County, Washington, or the federal court located in the Western District
of  Washington,  and  Company  consents  to  the  exclusive jurisdiction of such
courts.  In any action to enforce any right or remedy under this Agreement or to
interpret any provision of this Agreement, the prevailing Party will be entitled
to  recover  its  costs,  including  attorneys'  fees.

     11.4.     No Joint Venture.  Nothing in this Agreement will be construed to
               ----------------
mean  that any Party is appointed or in any way authorized to act as an agent of
any  other Party.  This Agreement does not create any joint venture, partnership
or  formal  business  entity  or  organization  of  any  kind.

     11.5.     Waiver.  No  waiver  of  any  provision of this Agreement will be
               ------
effective unless it is in a signed writing, and no such waiver will constitute a
waiver  of  any other provision(s) or of the same provision on another occasion.

     11.6.     Severability.  If  a  court  of  competent jurisdiction holds any
               ------------
term,  covenant  or  restriction  of  this  Agreement  to be illegal, invalid or
unenforceable, in whole or in part, the Parties agree to negotiate in good faith
to  create  an  appropriate  amendment  to  the  remaining  terms, covenants and
provisions  that  will  replicate the economic effect of the Parties' intentions
under  this  Agreement.

     11.7.     Injunctive  and  Equitable  Relief.  Each  Party acknowledges and
               ----------------------------------
agrees  that monetary damages may not be a sufficient remedy for a breach of the
terms  of  this  Agreement  respecting  Confidential  Information, and that such
breach  will  cause  the  owner  of  that Confidential Information immediate and
irreparable  injury.  In  such  cases, the non-breaching Party will be entitled,
without  waiving  or  prejudicing any other rights or remedies, to injunctive or
equitable  relief.

     11.8.     Entire  Agreement; Amendments.  This Agreement is not an offer by
               -----------------------------
Integral  and it is not effective until signed by both Parties.  This Agreement,
including the Exhibits attached hereto which are incorporated by this reference,
constitutes the entire agreement between the Parties with respect to the subject
matter  hereof  and  merges  all  prior  and  contemporaneous communications and
proposals, whether electronic, oral or written, between the Parties with respect
to  such  subject  matter.  This  Agreement  may

                      INTEGRAL PROPRIETARY AND CONFIDENTIAL
                                  PAGE 5 OF 6

<PAGE>
not  be  modified  except by a written agreement dated subsequent to the date of
this  Agreement  and  signed  by duly authorized representatives of Integral and
Company.

IN  WITNESS  WHEREOF, both Integral and Company have executed this Agreement, in
duplicate  originals  by  their  respective  officers  hereunto duly authorized.

================================================================================
INTEGRAL  TECHNOLOGIES,  INC.           KNOWLES  ELECTRONICS,  LLC

By:  /s/  William  S.  Robinson         By:  /s/  Robert  Walter

Title:  CEO                             Title:  Chief  Operating  Officer

Date:  Feb  9/07                        Date:  1/22/07
================================================================================

                      INTEGRAL PROPRIETARY AND CONFIDENTIAL
                                  PAGE 6 OF 6Exhibit 10.11

    
      

    

    

      AMENDMENT
        TO LICENSE AGREEMENT

      

      

      Amendment
        to License Agreement by and between TheraCour Pharma, Inc., ("Theracour")
        as Licensor, and NanoViricides, Inc., (“Nano”) as Licensee.

      

      
        The
          License Grant in paragraph 2 is amended and restated as follows:

        

        1)
          License
          Grant. Theracour hereby grants to Nano a limited, non-transferable.
          exclusive
          license,
          subject to the provisions of paragraph 2.2 as amended
          below, for the manufacture, use, sale, or offer of sale of the Licensed
          Product( s) in the Territory.

        

        2)
          Paragraph
          2.1 of the said License Agreement is amended to include “Rabies Virus”.

        

        3) Paragraph
          2.2 of the said License Agreement is clarified, superseded, and replaced
          by the following paragraph:

        

        “TheraCour
          retains exclusive rights to develop and synthesize the different TheraCour
          base polymers used for making the various nanoviricides. A TheraCour base
          polymer
          is defined as a polymer that does not have the virus-specific ligand attached
          to
          it as yet and its structure is covered in one or more of the specified
          TheraCour
          patents. TheraCour
          also retains the exclusive rights to research and develop the chemistries
          for
attaching
          the virus-specific ligands to the base polymers. A “ligand” is defined herein as
a
          chemical or biological moiety that is capable of binding to some feature
          of the
          targeted virus
          particle, this enabling targeting to a specific strain, subtype, type or
          class
          of virus, or
          broad
          or multiple classes of viruses. A ligand itself may be a small chemical
          moiety,
          a peptide
          moiety, a fragment of any antibody, an RNA or DNA “aptamer”, or another
chemically
          defined structure. A TheraCour base polymer is also referred to herein
          as a
“nanomicelle”.
          A nanomicelle is thus a component element of the Licensed Products. Further,
          TheraCour agrees to identify, design, and develop ligand(s) necessary for
          the
development
          of the Licensed Products. As to any Licensed Product, TheraCour retains
          the
          initial exclusive right to develop and synthesize the nanomicelles exclusively
          for Nano.
          In
          the event that Theracour is unable to supply the quantities of the
          nanomicelle(s) required
          for manufacture of the Licensed Product(s), then upon notice and after
          any
applicable
          cure periods required under the License agreement, Nano can acquire the
          nanomicelle(s) from other third party providers.

      

       

      
        	
                NanoViricides,
                  Inc.

              	 	
                TheraCour
                  Pharma, Inc.

              
	 	 	 
	/s/
                Eugene Seymour	 	
                /s/
                  Leo Ehrlich

              
	
                By
                  Eugene Seymour, President

              	 	
                By
                  Leo Ehrlich, Vice President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00117-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00117-of-00352.parquet"}]]